Evidence map›Paper›PMID 28941093›Full record

ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2017

Staging in bipolar disorder: from theoretical framework to clinical utility.

Michael Berk, Robert Post, Aswin Ratheesh, Emma Gliddon, Ajeet Singh, Eduard Vieta, Andre F Carvalho, Melanie M Ashton, Lesley Berk, Susan M Cotton and 4 more

Abstract read
In one paragraph

Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Biomarkers of neuroprogression and late staging in bipolar disorder: A systematic review.The Australian and New Zealand journal of psychiatry · 2023
    Pooled it
  3. Guideline
  4. Trial
  5. [Diagnostic transitions in adolescent inpatients with mental disorders: a retrospective cohort study].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. ADHD symptom trajectories across childhood and early adolescence and risk for hypomanic symptoms in young adulthood.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Observational

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael BerkIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.
Robert PostDepartment of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Aswin RatheeshOrygen, the National Centre of Excellence in Youth Mental Health, Parkville, Australia.
Emma GliddonIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.
Ajeet SinghIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.
Eduard VietaBipolar Disorders Program, Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
Andre F CarvalhoTranslational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Melanie M AshtonIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.
Lesley BerkIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.
Susan M CottonOrygen, the National Centre of Excellence in Youth Mental Health, Parkville, Australia.
Patrick D McGorryOrygen, the National Centre of Excellence in Youth Mental Health, Parkville, Australia.
Brisa S FernandesIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.
Lakshmi N YathamDepartment of Psychiatry, University of British Columbia, Vancouver, Canada.
Seetal DoddIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Illness staging is widely utilized in several medical disciplines to help predict course or prognosis, and optimize treatment. Staging models in psychiatry in general, and bipolar disorder in particular, depend on the premise that psychopathology moves along a predictable path: an at-risk or latency stage, a prodrome progressing to a first clinical threshold episode, and one or more recurrences with the potential to revert or progress to late or end-stage manifestations. The utility and validity of a staging model for bipolar disorder depend on its linking to clinical outcome, treatment response and neurobiological measures. These include progressive biochemical, neuroimaging and cognitive changes, and potentially stage-specific differences in response to pharmacological and psychosocial treatments. Mechanistically, staging models imply the presence of an active disease process that, if not remediated, can lead to neuroprogression, a more malignant disease course and functional deterioration. Biological elements thought to be operative in bipolar disorder include a genetic diathesis, physical and psychic trauma, epigenetic changes, altered neurogenesis and apoptosis, mitochondrial dysfunction, inflammation, and oxidative stress. Many available agents, such as lithium, have effects on these targets. Staging models also suggest the utility of stage-specific treatment approaches that may not only target symptom reduction, but also impede illness neuroprogression. These treatment approaches range from prevention for at-risk individuals, to early intervention strategies for prodromal and newly diagnosed individuals, complex combination therapy for rapidly recurrent illness, and palliative-type approaches for those at chronic, late stages of illness. There is hope that prompt initiation of potentially disease modifying therapies may preclude or attenuate the cognitive and structural changes seen in the later stages of bipolar disorder. The aims of this paper are to: a) explore the current level of evidence supporting the descriptive staging of the syndromal pattern of bipolar disorder; b) describe preliminary attempts at validation; c) make recommendations for the direction of further studies; and d) provide a distillation of the potential clinical implications of staging in bipolar disorder within a broader transdiagnostic framework.

Indexed as

biological markersBipolar disorderclinical stagingcognitive functioningearly interventionkindlinglithiumneuroprogressionneuroprotectiontransdiagnostic frameworktreatment outcome

Identifiers

PMID28941093
PMCPMC5608827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.